Despite current therapeutics and interventions, pain continues to pose a significant burden on a global scale. There are an estimated 100 million people living with chronic pain in the U.S., which is more than cancer, diabetes and heart disease combined, and approximately one quarter of these people live with daily, severe pain.
We are passionate and committed to addressing the substantial and growing chronic pain epidemic. We are advancing one of the largest, exclusively pain-focused pipelines of novel, non-opioid therapies in active development in order to bridge the safety and efficacy gaps in current chronic pain treatment. We aim to ease the burden that moderate to severe chronic pain places on patients and our healthcare system.
http://www.painmed.org/patientcenter/facts_on_pain.aspx, Last accessed December 21, 2017Learn More
Our company is led by a seasoned team of biotechnology and pharmaceutical executives with vast expertise in clinical development, commercial operations and business development, and an impressive and proven track record of developing and commercializing new safe and effective therapeutics.Meet Us
We’re redefining the study of pain therapies by using a three-pronged approach: 1) big data analytics to reveal the pain pathways where our analgesics will have the maximum therapeutic effect; 2) translational science to validate the safety and efficacy of our therapies in companion animals with the same naturally-occurring chronic pain conditions as humans; and 3) more efficient early-stage clinical trial strategies to inform and de-risk development.Learn More
Our pipeline consists of novel, non-opioid pain treatment therapeutics that are in development to potentially treat a broad array of chronic pain indications, including neuropathic, inflammatory and mixed pain (e.g., chronic back pain), without the risks of dependence or abuse. We believe that our pipeline is uniquely positioned to address the limitations of currently available therapies by providing safe, effective and long-term pain treatment solutions.Learn More
We are currently advancing several promising pipeline candidates for the treatment of an array of moderate to severe chronic pain conditions.Learn More
Feb. 21, 2018Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis PainOn February 21, Centrexion Therapeutics announced that the first patient has been dosed in its Phase 3 VICTORY-1 clinical trial of CNTX-4975, a synthetic, ultra-pure injection of trans-capsaicin, for the treatment of chronic moderate to severe pain due to knee osteoarthritis (OA).Learn More